Clinical Trials
Low-Dose Cyclophosphamide Maintenance Does Not Increase Second Malignancy Risk in RMS
Bisogno et alCancer

In an analysis of 1633 patients enrolled in the European RMS 2005 trial, maintenance chemotherapy with low-dose cyclophosphamide and vinorelbine was not associated with an increased risk of second malignant neoplasms (SMNs). While the addition of maintenance chemotherapy has improved survival outcomes for patients with high-risk pediatric rhabdomyosarcoma, concerns existed regarding cumulative exposure to alkylating agents.
At a median follow-up of 9.3 years (range, 0.6–17.7 years), 27 patients (1.7%) developed an SMN. SMNs occurred in 9 of 486 patients (1.9%) who received maintenance therapy compared to 17 of 1081 patients (1.6%) who did not receive maintenance (p = .75). The 8-year cumulative incidence of SMN across the overall cohort was estimated at 1.3% (95% CI, 0.8–2.0) using competing risk methodology.
Osteosarcoma was the most frequent SMN (n = 6), followed by low-grade glioma (n = 3), hematological malignancies (n = 3), and undifferentiated sarcoma (n = 2). Twenty of the 27 patients with an SMN received radiotherapy prior to SMN development, including 8 patients whose SMN developed within a previously irradiated field.
Genetic predisposition was identified as a major contributor to SMN development. Eight of the 27 patients had a known cancer predisposition syndrome, including Li-Fraumeni syndrome (LFS) in 6 patients and neurofibromatosis type 1 (NF1) in 2 patients; 3 of the 8 patients whose SMN arose in an irradiated field had LFS. The authors note that these findings support risk-adapted survivorship care and emphasize that longer follow-up is required to evaluate late-occurring SMNs.
Key Takeaways
- Maintenance chemotherapy was not associated with an increased risk of second malignant neoplasms compared to no maintenance therapy (1.9% [9 of 486] vs 1.6% [17 of 1081]; p = .75).
- The 8-year cumulative incidence of second malignant neoplasms was 1.3% (95% CI, 0.8–2.0) across the entire cohort, with known cancer predisposition syndromes identified in 8 of the 27 affected patients (Li-Fraumeni syndrome in 6, neurofibromatosis type 1 in 2).
Read the original sourceCancer
